Dietary fibre improves first-phase insulin secretion in overweight individuals - PubMed (original) (raw)

Randomized Controlled Trial

Dietary fibre improves first-phase insulin secretion in overweight individuals

Caroline L Bodinham et al. PLoS One. 2012.

Abstract

Previous work has shown increased insulin sensitivity, increased hepatic insulin clearance and lower postprandial insulin responses following treatment with resistant starch, a type of dietary fibre. The objective of this study was to further explore the effects of resistant starch on insulin secretion. Twelve overweight (BMI 28.2±0.4 kg/m(2)) individuals participated in this randomized, subject-blind crossover study. Participants consumed either 40 g type 2 resistant starch or the energy and carbohydrate-matched placebo daily for four weeks. Assessment of the effect on insulin secretion was made at the end of each intervention using an insulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT). Insulin and C-peptide concentrations were significantly higher during the FSIVGTT following the resistant starch compared with the placebo. Modelling of the data showed significantly improved first-phase insulin secretion with resistant starch. These effects were observed without any changes to either body weight or habitual food intake. This study showed that just four weeks of resistant starch intake significantly increased the first-phase insulin secretion in individuals at risk of developing type 2 diabetes. Further studies exploring this effect in individuals with type 2 diabetes are required.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: CLB received an educational fellowship from Premier Foods; this fellowship was independent to the research and was not involved in the study design, collection, analysis and interpretation of data, writing of the paper and/or decisions to submit the publication. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. The other authors have declared that no competing interests exist.

Figures

Figure 1

Figure 1. Glucose concentrations from FSIVGTT after 4 weeks daily supplementation with 40 g HAM-RS2 or placebo.

N = 12, mean ± SEM. No significant difference between the HAM-RS2 and placebo. Comparisons made with repeated measures ANOVA. Black circles = HAM-RS2; white circles = placebo; dashed line = baseline glucose concentrations.

Figure 2

Figure 2. Insulin concentrations from FSIVGTT after 4 weeks daily supplementation with 40 g HAM-RS2 or placebo.

N = 12, mean ± SEM. Significantly higher concentrations following HAM-RS2 compared with placebo (p = 0.009). Comparisons made with repeated measures ANOVA. Black circles = HAM-RS2; white circles = placebo.

Figure 3

Figure 3. C-peptide concentrations from FSIVGTT after 4 weeks daily supplementation with 40 g HAM-RS2 or placebo.

N = 12, mean ± SEM. Significantly higher concentrations following HAM-RS2 compared with placebo (p = 0.016). Comparisons made with repeated measures ANOVA. Black circles = HAM-RS2; white circles = placebo.

Similar articles

Cited by

References

    1. Standards of medical care in diabetes–2011. Diabetes Care. 2011;34:S11–61. - PMC - PubMed
    1. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes. 2002;51:S117–121. - PubMed
    1. Porte D. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes. 1991;40:166–180. - PubMed
    1. Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism. 1989;38:767–772. - PubMed
    1. Hosker JP, Burnett MA, Davies EG, Harris EA, Turner RC. Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. Diabetologia. 1985;28:809–814. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources